NEW YORK (GenomeWeb News) — Rosetta Genomics has inked an agreement under which Teva Pharmaceutical Industries will distribute three of the company’s microRNA-based molecular diagnostic cancer tests in Israel and Turkey.
Rosetta Genomics Chief Commercialization Officer Ronen Tamir said that because Israel has provided its citizens with health insurance under the National Health Law it is “a very attractive market,” adding that Turkey is “a country with significant market potential.”
The three tests covered under the agreement are from the company’s miRview line, including miRview Mets, miRview Squamous, and miRview Meso. The miRview Mets test identifies the primary tumor site in patients with metastatic cancer, and in those whose tumors have been labeled cancer of unknown primary. The squamous test differentiates squamous from non-squamous, non-small cell lung cancer patients. The meso test differentiates mesothelioma from other carcinomas found in the lung.
Financial terms of the agreement were not released.